top of page

Clear Scientific presents at 86th Annual Scientific Meeting of the College on Problems of Drug Dependence.

Montreal, Canada | June, 2024

Dr. Xinhua Li, Executive Vice President of Drug Development at Clear Scientific Inc, a Cambridge, MA biotech, presented a talk titled: A Novel Approach to Treat Xylazine and Opioid Intoxication at the 86th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD). The presentation outlined Clear Scientific’s approach using a novel sequestrant CS-1103 to treat intoxication from combinations of fentanyl and xylazine. The immediate and simultaneous sequestration of fentanyl and xylazine leads to rapid draining of these two intoxicants from the brain restoring respiration in 2-3 mins, and reducing the duration of xylazine sedation 5-fold. CS-1103 is effective to treat fentanyl in the context of co-use with other drugs of abuse such as methamphetamine and cocaine.


About Clear Scientific

Clear Scientific is a Cambridge, MA-based clinical stage biopharmaceutical company developing novel therapies for life-threatening and debilitating conditions caused by an excess of harmful substances in the body. CSInc is working closely with our co-founder Prof. George Whitesides at Harvard University, who pioneered the development of modern sequestrant-based therapeutics, and leading physicians at Massachusetts General Hospital.

For more information, visit

Recent Posts

See All


bottom of page